Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials

Fertility and Sterility

Volumn 103, Issue 4, 2015, Pages 923-930.e1

  Nelson, Scott M ^a   Klein, Bjarke M ^b   Arce, Joan Carles ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Antim llerian hormone; Antral follicle count; IVF clinic; Multicenter randomized controlled trial; Ovarian response

Indexed keywords

HUMAN MENOPAUSAL GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; RECOMBINANT FOLLITROPIN;

ADULT; ANTRAL FOLLICLE COUNT; ARTICLE; CONTROLLED OVARIAN STIMULATION; EMBRYO TRANSFER; FEMALE; FEMALE GENITAL TRACT PARAMETERS; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; METAPHASE; MULTICENTER STUDY (TOPIC); OOCYTE; OOCYTE RETRIEVAL; OVARY; OVULATION INDUCTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; BLOOD; CELL COUNT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOLOGY; INFERTILITY; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; OVARIAN RESERVE; OVARY FOLLICLE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE FACILITIES; ANTI-MULLERIAN HORMONE; CELL COUNT; FEMALE; HUMANS; INFERTILITY; OOCYTE RETRIEVAL; OVARIAN FOLLICLE; OVARIAN RESERVE; OVULATION INDUCTION; PREGNANCY; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84929487184     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2014.12.114     Document Type: Article

References (40)

1. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014;20:124-40.
2. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, et al. Antim ullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867-75.
3. Yates AP, Rustamov O, Roberts SA, Lim HY, Pemberton PW, Smith A, et al. Antimullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod 2011;26: 2353-62.
4. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;12:685-718.
5. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Antimullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113-30.
6. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil Steril 2013;99:963-9.
7. Elgindy EA, El-Haieg DO, El-Sebaey A. Antimullerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril 2008; 89:1670-6.
8. Jayaprakasan K, Campbell B, Hopkisson J, Johnson I, Raine-Fenning N. A prospective, comparative analysis of antimullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril 2010;93:855-64.
9. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Antim ullerian hormone as a predictor of IVF outcome. Reprod Biomed Online 2007;14:602-10.
10. Muttukrishna S, McGarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, antimullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG 2005;112: 1384-90.
11. Van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, Jong FH, et al. Serum antimullerian hormone levels: A novel measure of ovarian reserve. Hum Reprod 2002;17:3065-71.
12. Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, et al. Dynamic assays of inhibin B, antimullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 2005;20:3178-83.
13. Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of antimullerian hormone as a test for the prediction of ovarian reserve. Fertil Steril 2008;90:737-43.
14. Ficicioglu C, Kutlu T, Baglam E, Bakacak Z. Early follicular antimullerian hormone as an indicator of ovarian reserve. Fertil Steril 2006;85:592-6.
15. McIlveen M, Skull JD, Ledger WL. Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod 2007;22: 778-85.
16. Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009;91:705-14.
17. Broer SL, Dolleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: A meta-analysis. Hum Reprod Update 2011;17:46-54.
18. Anckaert E, Smitz J, Schiettecatte J, Klein B, Arce JC. The value of antimullerian hormone measurement in the long GnRH agonist protocol: Association with ovarian response, dose adjustments, embryo quality and pregnancy. Hum Reprod 2012;27:1829-39.
19. Arce JC, La Marca A, Klein BM, Andersen AN, Fleming R. Antimullerian hormone in GnRH antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good prognosis patients. Fertil Steril 2013;99: 1644-53.
20. Nyboe Andersen A, Witjes H, Gordon K, Mannaerts B, Xpect investigators. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod 2011;26:3413-23.
21. Nyboe Andersen A, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: A randomized assessor-blind controlled trial. Hum Reprod 2006;21: 3217-27.
22. Devroey P, Pellicer A, Nyboe Andersen A, Arce JC, Menopur in GnRH Antagonist Cycles with Single Embryo Transfer Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril 2012;97:561-71.
23. Broer SL, van Disseldorp J, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: An individual patient data approach. Hum Reprod Update 2013;19:26-36.
24. Broer SL, Dolleman M, van Disseldorp J, Broeze KA, Opmeer BC, Bossuyt PM, et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: An individual patient data meta-analysis. Fertil Steril 2013;100:420-9.e7.
25. Hansen KR, Morris JL, Thyer AC, Soules MR. Reproductive aging and variability in the ovarian antral follicle count: Application in the clinical setting. Fertil Steril 2003;80:577-83.
26. Jayaprakasan K, Hopkisson JF, Campbell BK, Clewes J, Johnson IR, Raine-Fenning NJ. Quantification of the effect of pituitary down-regulation on 3D ultrasound predictors of ovarian response. Hum Reprod 2008;23: 1538-44.
27. Sharara FI, Lim J, McClamrock HD. The effect of pituitary desensitization on ovarian volume measurements prior to in-vitro fertilization. Hum Reprod 1999;14:183-5.
28. Yu Ng EH, Chi Wai Chan C, Tang OS, Shu Biu Yeung W, Chung Ho P. Effect of pituitary downregulation on antral follicle count, ovarian volume and stromal blood flow measured by three-dimensional ultrasound with power Doppler prior to ovarian stimulation. Hum Reprod 2004;19: 2811-5.
29. Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, et al. Definition and significance of polycystic ovarian morphology: A task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014;20:334-52.
30. Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of antimullerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2014 Dec 8. pii: dmu062. [Epub ahead of print].
31. Gougeon A. Dynamics of follicular growth in the human: A model from preliminary results. Hum Reprod 1986;1:81-7.
32. Deb S, Jayaprakasan K, Campbell BK, Clewes JS, Johnson IR, Raine-Fenning NJ. Intraobserver and interobserver reliability of automated antral follicle counts made using three-dimensional ultrasound and SonoAVC. Ultrasound Obstet Gynecol 2009;33:477-83.
33. Deb S, Campbell BK, Clewes JS, Raine-Fenning NJ. Quantitative analysis of antral follicle number and size: A comparison of two-dimensional and automated three-dimensional ultrasound techniques. Ultrasound Obstet Gynecol 2010;35:354-60.
34. Broekmans FJ, de Ziegler D, Howles CM, Gougeon A, Trew G, Olivennes F. The antral follicle count: practical recommendations for better standardization. Fertil Steril 2010;94:1044-51.
35. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. The physiology and clinical utility of antimullerian hormone in women. Hum Reprod Update 2014;20:370-85.
36. Gassner D, Jung R. First fully automated immunoassay for antimullerian hormone. Clin Chem Lab Med 2014;52:1143-52.
37. Greenland S, Robins JM. Identifiability, exchangeability, and epidemiological confounding. Int J Epidemiol 1986;15:413-9.
38. McNamee R. Confounding and confounders. Occup Environ Med 2003;60: 227-34.
39. Weinberg CR. Toward a clearer definition of confounding. Am J Epidemiol 1993;137:1-8.
40. Iliodromiti S, Kelsey TW, Wu O, Anderson RA, Nelson SM. The predictive accuracy of antimullerian hormone for live birth after assisted conception: A systematic review and meta-analysis of the literature. Hum Reprod Update 2014;20:560-70.